COMMUNIQUÉS West-GlobeNewswire

-
HOOPP announces changes to its Executive Leadership Team
09/07/2025 -
Sanofi: Information concerning the total number of voting rights and shares - June 2025
09/07/2025 -
Sanofi: Informations relatives au nombre de droits de vote et d'actions - Juin 2025
09/07/2025 -
Press release: Transparency Notification from Shareholders
09/07/2025 -
EssilorLuxottica: Disclosure of Share Capital and Voting Rights Outstanding as of June 30, 2025
09/07/2025 -
EssilorLuxottica: Nombre total de droits de vote et d’actions composant le capital social au 30 juin 2025
09/07/2025 -
GUERBET : Bilan semestriel du contrat de liquidité
09/07/2025 -
Bavarian Nordic Enters New Smallpox/Mpox Vaccine Supply Contract with European Country
09/07/2025 -
A Life Rewritten: KFSHRC Treats Rare Disease After 22 Years of Specialized Care
09/07/2025 -
FDA Grants Fast Track Designation for TRE-515 in Combination with Radiation Therapy for the Treatment of Metastatic Castration Resistant Prostate Cancer
09/07/2025 -
FDA Clears Updated Magstim Rapid Transcranial Magnetic Stimulation Research System
09/07/2025 -
INVO Fertility Enhances INVOcell Technology with Expanded Awareness, Training, and Improved Pricing
09/07/2025 -
Connect Biopharma’s Exclusive Licensee in China, Simcere Pharmaceutical, Announced Submission of its New Drug Application for Rademikibart for the Treatment of Atopic Dermatitis in China
09/07/2025 -
Dandy Launches America’s First Two-Visit Dentures for Medicaid, Medicare, and Low-Paying PPOs
09/07/2025 -
Palisade Bio Appoints Emil Chuang, MB BS FRACP to its Board of Directors
09/07/2025 -
Qanatpharma, Zuse Institute Berlin, Enamine, and Proteros biostructures Announce Generative-AI Driven Lead Discovery Collaboration
09/07/2025 -
Moleculin Expands Phase 3 MIRACLE Clinical Trial into the Country of Georgia, Enrollment Update and Future Plans
09/07/2025 -
Silexion Therapeutics Announces Positive Results in Preclinical Study Demonstrating Significant SIL204 Efficacy in Human Lung Cancer Cell Lines
09/07/2025 -
Adial Pharmaceuticals Files PCT Patent Application to Protect Core Assets and Extend IP Exclusivity on Core Technology to at least 2045
09/07/2025
Pages